Literature DB >> 10435585

Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway.

P Chaturvedi1, W K Eng, Y Zhu, M R Mattern, R Mishra, M R Hurle, X Zhang, R S Annan, Q Lu, L F Faucette, G F Scott, X Li, S A Carr, R K Johnson, J D Winkler, B B Zhou.   

Abstract

In response to DNA damage and replication blocks, cells activate pathways that arrest the cell cycle and induce the transcription of genes that facilitate repair. In mammals, ATM (ataxia telangiectasia mutated) kinase together with other checkpoint kinases are important components in this response. We have cloned the rat and human homologs of Saccharomyces cerevisiae Rad 53 and Schizosaccharomyces pombe Cds1, called checkpoint kinase 2 (chk2). Complementation studies suggest that Chk2 can partially replace the function of the defective checkpoint kinase in the Cds1 deficient yeast strain. Chk2 was phosphorylated and activated in response to DNA damage in an ATM dependent manner. Its activation in response to replication blocks by hydroxyurea (HU) treatment, however, was independent of ATM. Using mass spectrometry, we found that, similar to Chk1, Chk2 can phosphorylate serine 216 in Cdc25C, a site known to be involved in negative regulation of Cdc25C. These results suggest that Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Activation of Chk2 might not only delay mitotic entry, but also increase the capacity of cultured cells to survive after treatment with gamma-radiation or with the topoisomerase-I inhibitor topotecan.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435585     DOI: 10.1038/sj.onc.1202925

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  112 in total

Review 1.  DNA replication blockade impairs p53-transactivation.

Authors:  R Takimoto; W S El-Deiry
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

2.  Phosphorylation and rapid relocalization of 53BP1 to nuclear foci upon DNA damage.

Authors:  L Anderson; C Henderson; Y Adachi
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

Review 3.  Cell cycle checkpoints and their inactivation in human cancer.

Authors:  M Molinari
Journal:  Cell Prolif       Date:  2000-10       Impact factor: 6.831

4.  Radiation-induced phosphorylation of Chk1 at S345 is associated with p53-dependent cell cycle arrest pathways.

Authors:  Hui Tian; Alexander T Faje; Siu Lan Lee; Timothy J Jorgensen
Journal:  Neoplasia       Date:  2002 Mar-Apr       Impact factor: 5.715

Review 5.  Control of the G2/M transition.

Authors:  George R Stark; William R Taylor
Journal:  Mol Biotechnol       Date:  2006-03       Impact factor: 2.695

6.  Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2.

Authors:  Harry A Rogoff; Mary T Pickering; Fiona M Frame; Michelle E Debatis; Yolanda Sanchez; Stephen Jones; Timothy F Kowalik
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

7.  Functional characterization of a cancer causing mutation in human replication protein A.

Authors:  Cathy S Hass; Lokesh Gakhar; Marc S Wold
Journal:  Mol Cancer Res       Date:  2010-06-29       Impact factor: 5.852

8.  Nuclear reorganization and homologous chromosome pairing during meiotic prophase require C. elegans chk-2.

Authors:  A J MacQueen; A M Villeneuve
Journal:  Genes Dev       Date:  2001-07-01       Impact factor: 11.361

9.  Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein.

Authors:  Mikhail Lomonosov; Shubha Anand; Mahesh Sangrithi; Rachel Davies; Ashok R Venkitaraman
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

10.  Large T antigen promotes JC virus replication in G2-arrested cells by inducing ATM- and ATR-mediated G2 checkpoint signaling.

Authors:  Yasuko Orba; Tadaki Suzuki; Yoshinori Makino; Kanako Kubota; Shinya Tanaka; Takashi Kimura; Hirofumi Sawa
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.